1	Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in
2	9/11 responders
3	
4	Monika A. Waszczuk, PhD ¹ , Olga Morozova, PhD ² , Elizabeth Lhuillier, MD ^{3,4} , Anna R.
5	Docherty, PhD ^{5,6} , Andrey A. Shabalin, PhD ^{5,6} , Xiaohua Yang, MS ⁴ , Melissa A. Carr, Ms ³ , Sean
6	A. P. Clouston, PhD ⁷ , Roman Kotov, PhD ⁸ , and Benjamin J. Luft, MD ^{3,4}
7	
8	¹ Department of Psychology, Rosalind Franklin University of Medicine and Science, North
9	Chicago, IL
10	² Department of Public Health Sciences, Biological Sciences Division, University of Chicago,
11	Chicago, IL
12	³ World Trade Center Health and Wellness Program, Stony Brook University, Stony Brook, NY
13	⁴ Department of Medicine, Stony Brook University, Stony Brook, NY
14	⁵ Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT
15	⁶ Huntsman Mental Health Institute, Salt Lake City, UT
16	⁷ Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony
17	Brook University, Stony Brook, NY
18	⁸ Department of Psychiatry, Stony Brook University, Stony Brook, NY
19	
20	

21 Corresponding author:

- 22 Benjamin J. Luft, MD
- 23 Email: <u>Benjamin.Luft@stonybrookmedicine.edu</u>

24 ORCID IDs:

- 25 Monika A. Waszczuk: 0000-0003-1775-1970
- 26 Olga Morozova: 0000-0001-7606-8413
- 27 Anna R. Docherty: 0000-0001-7139-7007
- 28 Andrey A. Shabalin: 0000-0003-0309-6821
- 29 Melissa Carr: 0000-0002-0870-6628
- 30 Roman Kotov: 0000-0001-9569-8381
- 31 Benjamin J. Luft: 0000-0001-9008-7004

32

- 33 Abstract: 198 words
- 34 Manuscript: 3,514 words
- 35 **Tables:** 4
- 36 **References:** 29

37

Abstract

40 Background. Genetic factors contribute to individual differences in the severity of coronavirus disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic 41 risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19 42 severity or post-acute COVID-19 in community-dwelling individuals. Methods. Participants in 43 this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2 44 45 (mean age at infection=56.06; 93.4% male; 82.7% European ancestry). Seventy-five (7.6%) responders were in the severe COVID-19 category; 306 (31.1%) reported at least one post-acute 46 COVID-19 symptom at 4-week follow-up. Analyses were adjusted for population stratification 47 48 and demographic covariates. Findings. The asthma PRS was associated with severe COVID-19 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-49 19 symptomatology (β =.09, p=.01), independently of respiratory disease diagnosis. Severe 50 51 COVID-19 category was also associated with the allergic disease PRS (OR=1.97, [1.26-3.07]) 52 and the PRS for COVID-19 hospitalization (OR=1.35, [1.01-1.82]). PRS for coronary artery disease and type II diabetes were not associated with COVID-19 severity. Conclusion. Recently 53 developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization 54 capture some of the individual differences in severity and clinical course of COVID-19 illness in 55 56 a community population.

57

58 Keywords: 9/11 responders; COVID-19; SARS-CoV-2; post-acute COVID-19 syndrome;
59 polygenic risk score; asthma; allergic disease

Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in 9/11 responders

63 Introduction

64 Coronavirus disease 2019 (COVID-19) is caused by an infection by the severe acute respiratory 65 syndrome coronavirus (SARS-CoV-2) and remains a pandemic in the US and globally [1]. 66 COVID-19 invades the respiratory and other crucial systems in the body, varying widely in 67 severity, from asymptomatic presentation to severe outcomes including hospitalization or death. 68 Moreover, at least one-third of individuals with COVID-19 develop post-acute COVID-19 syndrome [2], which consists of residual respiratory, fatigue, central nervous system, and 69 70 musculoskeletal symptoms that persist at least four weeks after initial symptom onset [3, 4]. Despite vaccination efforts, the potentially severe and chronic outcomes of COVID-19 71 necessitate a better characterization of individuals at elevated risk for clinically significant 72 disease outcomes. 73

74 Across a range of studies, COVID-19 severity was found to be associated with clinical risk 75 factors such as older age, male sex, smoking, respiratory illness, cardiovascular disease, and 76 immunocompromised status [5-7]. Moreover, a person's own genetic factors critically affect individual differences in COVID-19 disease severity [8]. Large-scale, population-based genome-77 wide association studies (GWAS) indicate that multiple common genetic variants can contribute 78 79 to COVID-19 symptom severity after infection [9]. Genes that emerged from GWAS most strongly associated with severe COVID-19 progression are involved in immune response and 80 81 lung disease pathology. The individual variants associated with disease severity in the discovery GWAS have minor effects, but cumulatively they explain a substantial proportion of genetic 82

variation in response to the virus. Common variants can be collapsed into a polygenic risk score
(PRS) to improve the prediction of at-risk patients in an independent cohort. For each individual,
the number of risk alleles carried at each variant (0, 1, or 2) can be summed and weighted by its
effect size, resulting in a single score of each individual's genetic vulnerability to COVID-19
severity.

88 COVID-19 PRS have shown to be associated with increased risk of morbidity and mortality due 89 to COVID-19 in several independent samples and across ancestries, with PRS outperforming individual genetic variants and providing information over and above established risk factors 90 91 [10-13]. While the COVID-19 PRS was designed to capture all genes associated with the 92 severity of COVID-19, the studies relied partially on the UK Biobank cohort, which has limited phenotypic information on COVID-19 disease and exposure status of controls, largely based on 93 electronic medical records of laboratory test results and ICD-10 codes for COVID-19 and 94 respiratory support. It is therefore plausible that other PRS capture genetic vulnerability to other 95 conditions, such as asthma or coronary artery disease, that might also associate with COVID-19 96 97 symptom severity or COVID-19 clinical course, although empirical evidence is limited. For example, only one published study has reported no association between asthma PRS and severe 98 99 COVID-19 [14], but no other studies to our knowledge have examined post-acute COVID-19 symptoms. 100

101 Therefore, the present study translated genetic discoveries in COVID-19 host genetics to an 102 independent, well-characterized patient population with a full range of COVID-19 severity. 103 Responders to the World Trade Center (WTC) attacks on September 11, 2001 are a cohort with 104 detailed prospective health data, including information on COVID-19 infection, symptom 105 severity, and follow-up outcomes. Our team has previously demonstrated that younger and

106 employed responders were at a higher risk of being infected with the SARS-CoV-2 virus [15]. 107 Among those who experienced infection, a pre-existing obstructive airway disease diagnosis predicted an elevated risk for a more severe COVID-19 presentation [2]. The risk of developing 108 109 post-acute COVID-19 sequelae was similarly elevated in responders with respiratory problems as well as heart disease, over and above the risk conferred by the COVID-19 severity itself. 110 While respiratory and other chronic conditions are associated with toxic exposures during the 111 112 9/11 disaster, some of the individual differences in post-exposure outcomes in 9/11 responders can be attributed to genetic vulnerabilities [16, 17]. 113

114 Relatively little work describing genetic risk to COVID-19 severity has been conducted in 115 community individuals with a full range of symptom severity. The associations between PRS and a common long-term outcome of post-acute COVID-19 also remain unknown. Thus, building on 116 117 our previous work in the large sample of WTC responders who were infected with SARS-CoV-2, we investigated whether polygenic vulnerabilities to COVID-19 hospitalization, as well as to 118 119 asthma, related allergic diseases, coronary artery disease, and type II diabetes, were associated 120 with COVID-19 severity and post-acute COVID-19 symptoms, after adjusting for established 121 risk factors. We investigated genetic associations with a full range of COVID-19 symptoms, as well as genetic risk for the severe COVID-19, which has the highest clinical relevance as it 122 includes hospitalized cases. Based on previous findings, we hypothesized that PRS for COVID-123 19 hospitalization would be significantly associated with COVID-19 severity across a range of 124 125 symptoms, and would help identify the most severe COVID-19 group. We tentatively hypothesized that PRS for asthma, allergic disease, coronary artery disease, and type II diabetes 126 would be associated with worse COVID-19 severity outcomes and that the polygenic 127 128 associations would extend to development of post-acute COVID-19 sequelae. We

129 Methods

130 Participants and Procedure

Participants were 983 WTC responders enrolled in a prospective cohort called the WTC Health 131 Program which was established in 2002 and independently monitors the health of more than 132 13,000 WTC first responders living on Long Island, NY, USA [18]. The analytic sample 133 comprised of all genotyped participants from an established cohort of responders with the first 134 instance of SARS-CoV-2 infection before January 2022, with the median infection date of 135 136 December 2020 [2]. The mean age of the analytic sample at infection was 56.06, SD=7.37, range= 39.79-89.04, 93.4% of the sample was male, and 82.3% had European ancestry. The 137 analytic sample did not differ significantly from the total cohort of responders with SARS-CoV-138 139 2 infection (N=1,280) on demographic and symptom variables (all p-values for independent 140 sample t-tests and chi-square tests >0.05).

The analytic sample included responders with a verified history of a positive polymerase chain 141 142 reaction, antigenic, or antibody test for SARS-CoV-2 or positivity for antibodies to SARS-CoV-2 nucleocapsid protein according to medical or laboratory records (N=587), as well as 143 responders who reported a positive laboratory test for SARS-CoV-2, but for whom documented 144 145 proof of the test results was not available (N=396). The unverified cases did not differ significantly from verified cases on all study variables, except for lower COVID-19 severity 146 147 (t(df)=2.30 (847.60), p=.02, d=.15). Verifiable hospitalization records at local hospitals increased 148 the likelihood of objectively verifying the most severe responders. Analyses adjusted for verification status. All cases represent a first instance of SARS-CoV-2 infection. 149

150 Clinical information on initial and residual COVID-19 symptoms was collected irrespective of 151 verification status through in-person questionnaires, surveys sent via email and text, electronic medical records obtained with the release of health information forms, and follow-up calls. 152 153 Symptoms of COVID-19 in this study included respiratory symptoms (i.e., shortness of breath, chest pain, sore throat, congestion/runny nose, and wheezing), systemic symptoms (i.e., fever, 154 fatigue, headache, chills, and weight loss), gastrointestinal symptoms (i.e., nausea, vomiting, and 155 156 diarrhea), musculoskeletal symptoms (i.e., joint and muscle pain), central nervous system symptoms (i.e., dizziness, vertigo, loss of smell/taste, and brain fog), and psychiatric symptoms 157 158 (i.e., anxiety, depression, and post-traumatic stress disorder [PTSD]).

Blood samples for genotyping were drawn at the WTC Health Program clinic as a routine part of the monitoring examination from January 2012 to January 2019. The study was approved by the Institutional Reviewer Board of Stony Brook University, and all participants provided written informed consent. For more information on the study design, see Lhuillier, Yang [2].

163 Measures

164 **COVID-19 severity**

Participants in the analytic sample were categorized into four severity groups according to their symptoms: asymptomatic (N=92, 9.4%), mild (N=378, 38.5%), moderate (N=408, 41.5%), and severe (N=75, 7.6%). This categorization was based on the NIH COVID-19 clinical spectrum updated October 2021 (National Institutes of Health, 2021). The asymptomatic category consisted of responders who reported a positive SARS-CoV-2 virologic test result without any symptoms associated with COVID-19. The mild category included responders with at least one symptom associated with COVID-19 but no shortness of breath or difficulty breathing. Moderate

172 cases were in responders who reported shortness of breath and/or diagnosis of lower respiratory 173 disease (pneumonia/bronchitis) during clinical assessment or imaging. These responders 174 maintained oxygen saturation $(SpO_2) \ge 94\%$ on room air at sea level. Mild and moderate cases 175 were medically managed primarily at home, even if they initially visited a healthcare facility for medical treatment and/or testing. Severe cases included responders with SpO₂<93% on room air, 176 respiratory rate >30 breaths/min, heart rate greater than 100 beats per minute, acute respiratory 177 178 distress syndrome, septic shock, cardiac dysfunction, or an exaggerated inflammatory response 179 in addition to pulmonary disease, or severe illness causing cardiac, hepatic, renal, central nervous 180 system, or thrombotic disease during COVID-19. Responders were also categorized as severe if they were admitted to the hospital, or received intensive care or mechanical ventilation, or if they 181 eventually died from COVID-19. 182

183 Two complimentary analytic variables were created: an ordinal COVID-19 severity variable on 184 1-4 scale corresponding to asymptomatic, mild, moderate, and severe symptoms, and a binary 185 COVID-19 severe category variable, with asymptomatic, mild, and moderate patients in one 186 category, and severe patients in the second category.

187 Post-acute COVID-19 symptoms

Residual symptoms were defined as any COVID-19-related symptoms that lasted at least 4 weeks after symptom onset (Centers for Disease Control and Prevention, 2021b). Residual symptoms included respiratory problems (e.g., dyspnea, chest discomfort, cough, and fatigue), CNS symptoms (e.g., loss or reduction of smell/taste, mental fog, dizziness, and vertigo), and musculoskeletal complaints. In the analytic sample, N=306 (31.1%) participants reported at least

one residual COVID-19 symptom. A binary analytic variable was created to compareparticipants with and without at least one residual symptoms.

195 **Covariates**

Electronic medical records updated on January 1, 2020, were used to obtain date of birth to 196 calculate age at infection, obstructive airway disease and upper respiratory disease diagnoses, 197 lifetime posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) diagnoses. 198 199 and the most recent available measure of body mass index (BMI). Obstructive airway disease 200 category includes diagnoses of asthma and bronchitis, upper respiratory disease includes chronic 201 rhinitis and chronic sinusitis [18]. Respiratory diagnoses were determined based on systemic examination by a physician or nurse practitioner and included repeated pulmonary function tests, 202 203 physical examination, and medical history. BMI scores were analyzed as continuous variable to maximize statistical power [19, 20]. Genetic data were used to obtain sex and ancestry 204 information. 205

206 Genetic data processing and polygenic risk scores (PRS)

207 Genotyping of blood samples was performed at the Genomics Shared Resource at Roswell Park Cancer Institute, using the Infinium Global Screening Array (Illumina, San Diego, CA, USA), 208 209 according to manufacturer protocols. Genotypes were imputed on the Michigan Imputation Server pipeline v1.2.4, using the Haplotype Reference Consortium reference panel [21]. Before 210 imputation, the genotypes were filtered for ambiguous strand orientation, missingness rate>5% 211 212 (by marker exclusion, then by individual), Hardy-Weinberg equilibrium violation ($p < 10^{-6}$), and sex mismatch. After imputation, the single-nucleotide polymorphisms (SNPs) were excluded for 213 imputation $R^2 < 0.5$ and the average call rate below 90%. Genotype imputation was performed on 214

552,230 SNPs, resulting in 25,514,638 SNPs after quality control, which were used for matching
to discovery GWAS variants for the final polygenic risk scoring.

217

218 PRS were created using PRSice 2.0 [22]. PRS were created by aggregating genetic variants that 219 emerged from the GWAS of the phenotype of interest, i.e. the GWAS discovery sample. Our 220 primary analysis used a complete list of SNPs after clumping, and their corresponding weights 221 from GWAS discovery samples (P-value threshold=1) to incorporate more of the genome [23]. All analyses adjusted for the first ten genetic ancestry principal components (PCs). Primary 222 223 analyses were conducted on participants of European ancestry due to the discovery GWAS being 224 European; however, sensitivity analyses in the entire sample are also reported in the 225 Supplementary Materials.

PRS for asthma and allergic disease were based on two GWAS conducted on participants of European ancestry from the UK Biobank [24]. The asthma GWAS was conducted in 90,853 individuals, 14,085 physician-diagnosed asthma cases, and 76,768 controls without asthma or allergic diseases. Asthma is heterogeneous phenotype and cases with allergic, non-allergic, mixed, and other forms of asthma were included in GWAS. The allergic disease GWAS was conducted in 102,453 individuals, 25,685 with doctor-diagnosed hay fever, allergic rhinitis, eczema, or allergic asthma cases, and 76,768 controls without asthma or allergic disease.

The coronary artery disease PRS was based on a GWAS meta-analysis conducted in 122,733 coronary artery disease cases and 424,528 controls from the UK Biobank and the CARDIoGRAMplusC4D Consortium [25]. Cases included patients with coronary artery disease diagnosis or treatment indicated in their electronic medical record or self-reported heart attack/myocardial infarction, coronary angioplasty, or heart bypass. The control group excluded

participants who reported that their mother, father, or sibling suffered from heart disease. The
type II diabetes PRS was based on a GWAS meta-analysis in 62,892 type II diabetes cases and
596,424 controls of European ancestry [26].

241 PRS for COVID-19 severity were based on summary statistics from two GWAS meta-analyses conducted by the COVID-19 Host Genetics Initiative [9] release 6, dated June 15, 2021. This 242 243 initiative is an international collaboration spanning 61 studies from 24 countries. The first 244 GWAS was performed in 2,085,803 individuals, contrasting 24,274 patients hospitalized due to COVID-19 with 2,061,529 population controls presumed to be COVID-19 negative (COVID-245 246 PRS hospitalized vs. population). The second GWAS was conducted in 87,671 patients with 247 COVID-19, contrasting 14,480 hospitalized patients with 73,191 non-hospitalized patients (COVID-PRS hospitalized vs. not-hospitalized). 248

249 Analytic approach

250 Linear regression was used to test whether PRS is associated with ordinal COVID-19 severity. 251 Logistic regression was used to test whether PRS is associated with the severe COVID-19 252 category classification (severe vs. moderate/mild/asymptomatic), and the presence of post-acute 253 COVID-19 symptoms. Continuous variables were standardized prior to analysis by transforming 254 them to Z scores with a mean of zero and standard deviation of one. Models were adjusted for 255 the first ten principal components of the population structure, COVID-19 verification status, age, 256 and sex. Models testing asthma and allergic disease PRS were further adjusted for obstructive 257 airway disease and upper respiratory disease diagnoses to ensure that associations do not merely 258 reflect respiratory illness status. A supplementary analysis further adjusting for PTSD and MDD 259 diagnoses was conducted for asthma PRS, to test the potential role of mental health in the

associations. Likewise, models testing PRS for coronary artery disease and type II diabetes further adjusted for BMI. Models testing associations with residual symptoms additionally adjusted for COVID-19 severity. Separate models were conducted for each PRS. The primary analyses were conducted in participants of European ancestry. Given that COVID-19 GWAS were completed using multi-ancestry participants, for sensitivity testing and inclusivity results are also reported for participants of all ancestries in Supplementary Materials. All analyses used nominal p-value threshold <.05 and were conducted in SPSS version 28 and R version 4.1.0.

267 Role of the funding source

The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

270 **Results**

Descriptive statistics for the European ancestry sample are reported in Table 1. Many responders (N=57, 7.0%) had severe COVID-19. In total, 247 (30.4%) responders reported at least one residual COVID-19 symptom. Correlations between PRS are reported in Supplementary Table S1.

Table 1 – Descriptive statistics for participants of European ancestry.

277

N total	813		
N male (%)	772 (95.0%)		
Mean age at infection (SD), range	56.06 (7.37), 39.79-89.04		
N OAD diagnosis (%)	312 (38.4%)		
N URD diagnosis (%)	525 (64.6%)		
N PTSD and/or MDD diagnosis (%)	124 (15.3%)		
Mean BMI (SD), range	31.34 (5.08),19.48-62.18		
N COVID-19 severity (%)			
Asymptomatic	78 (9.6%)		
Mild	320 (39.4%)		
Moderate	332 (40.8%)		
Severe	57 (7.0%)		
Missing	26 (3.2%)		
N any residual symptoms	247 (30.4%)		

278

279 *Notes:*

280 OAD – Obstructive airway disease; URD – upper respiratory disease; PTSD-Posttraumatic stress

281 disorder, MDD – Major depressive disorder, BMI – body mass index; COVID-19 – coronavirus

disease 2019; SD - standard deviation.

283

285 The PRS for asthma was significantly associated with COVID-19 severity in the European 286 ancestry subsample (β =.09, p=.01), adjusting for co-occurring obstructive airway disease 287 diagnoses and upper respiratory disease diagnoses, Table 2. Likewise, the PRS for asthma was 288 associated with COVID-19 severe category (OR=1.61, [1.17-2.21]). Allergic disease PRS showed a similar pattern, significantly associating the COVID-19 severe category (OR=1.97, 289 [1.26-3.07]). Associations with residual COVID-19 symptoms were not significant. There were 290 291 no significant associations between coronary artery disease or type II diabetes PRS, and COVID-292 19 phenotypes (Table 3). The COVID-19 PRS based on the GWAS contrasting hospitalized 293 cases vs. controls was significantly associated with the COVID-19 severe category in sample 294 with European ancestry (OR=1.35, [1.01-1.82]), Table 4. Conversely, the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized cases did not reach 295 296 significance in the European ancestry subsample. Moreover, none of the COVID-19 PRS were 297 associated with the full range of COVID-19 severity, nor the presence of any residual symptoms.

299 Table 2– Associations between allergic disease and asthma PRS and COVID-19 severity

301			
	COVID-19	COVID-19 severe	Any residual
	severity	category	symptoms
PRS: Asthma	β=.09, <i>p</i> =.01	<i>OR</i> =1.61	<i>OR</i> =1.07
		(CI: 1.17-2.21), <i>p</i> <.01	(CI: .90-1.27), <i>p</i> =.43
PRS: Allergic disease	$\beta = .09, p = .06$	<i>OR</i> =1.97	<i>OR</i> =.89
		(CI: 1.26-3.07), <i>p</i> <.01	(CI: .70-1.13), <i>p</i> =.34

300 and residual symptoms in participants of European ancestry.

302

303 *Notes:*

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at infection, sex, obstructive airway disease diagnosis, upper respiratory disease diagnosis. Models with residual symptoms as a dependent variable were additionally adjusted for COVID-19 severity. Associations between asthma PRS and COVID-19 outcomes were not affected by lifetime PTSD and MDD diagnoses, see Supplementary Table S6.

311

313 Table 3 – Associations between coronary artery disease and type II diabetes PRS and

314 COVID-19 severity and residual symptoms in participants of European ancestry.

315	
-----	--

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Coronary artery disease	β=.05, <i>p</i> =.21	<i>OR</i> =1.06	<i>OR</i> =1.22
		(CI: .70-1.60), <i>p</i> =.79	(CI: .97-1.53), <i>p</i> =.09
PRS: Type II diabetes	β =.04, p=.32	<i>OR</i> =1.42	<i>OR</i> =.71
		(CI: .80-2.53), <i>p</i> =.23	(CI: .50-1.01), <i>p</i> =.05

317 *Notes:*

316

318 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:

319 coronavirus disease 2019. All models are adjusted for the first ten principal components of the

population structure, verification status, age at infection, sex, and BMI. Models with residual

321 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

322

324 Table 4 – Associations between COVID-19 PRS and COVID-19 severity and residual

325 symptoms in participants of European ancestry.

326

520			
	COVID-19	COVID-19 severe	Any residual
	severity	category	symptoms
PRS: COVID-19 hospitalized vs. controls	β =.03, p=.40	OR=1.35	OR=1.11
		(CI: 1.01-1.82), <i>p</i> =.04	(CI: .93-1.33), <i>p</i> =.24
PRS: COVID-19 hospitalized vs. not-	β=.05, <i>p</i> =.23	<i>OR</i> =1.27	<i>OR</i> =1.08
hospitalized		(CI: .95-1.69), <i>p</i> =.12	(CI:.90-1.29), <i>p</i> =.41
327			

328 *Notes:*

329 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:

coronavirus disease 2019. All models are adjusted for the first ten principal components of the

331 population structure, verification status, age at infection, and sex. Models with residual

332 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

333

334

335

337 Sensitivity analyses

338 Descriptive statistics for total sample with participants of all ancestries are reported in Supplementary Table S2. In the total sample, adjusting for respiratory disease diagnoses, the 339 PRS for asthma was significantly associated with COVID-19 severity (β =.08, p=.01) and 340 341 COVID-19 severe category (OR=1.53, [1.15-2.03]), and the allergic disease PRS was associated with the COVID-19 severe category (OR=1.86, [1.25-2.77]), Supplementary Table S3. There 342 were no significant associations between coronary artery disease or type II diabetes PRS, and 343 344 COVID-19 phenotypes, Supplementary Table S4. The COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. controls was significantly associated with the COVID-19 345 346 severe category in the whole sample (OR=1.42, [1.11-1.82]), Supplementary Table S5. Likewise, the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized 347 cases was also significantly associated with COVID-19 severe category in the total sample 348 349 (*OR*=1.33, [1.04-1.69]). Accounting for PTSD and MDD diagnoses did not alter associations 350 between asthma PRS and COVID-19 outcomes, see Supplementary Table S6.

351 **Discussion**

The current study reports associations between recently developed polygenic biomarkers and COVID-19 severity in a community-based population of responders to the WTC disaster who had COVID-19. We found that the PRS for asthma, allergic diseases, and COVID-19 severity were elevated in the severe COVID-19 category responders.. Asthma PRS was additionally associated with COVID-19 symptomatology across the full spectrum of COVID-19 severity. No significant associations were observed for PRS for coronary artery disease and type II diabetes. Moreover, PRS were not associated with post-acute COVID-19 sequelae. These findings add to

the growing body of evidence to suggest that existing polygenetic profiles could be informativeabout the risk for severe COVID-19 presentation, despite the small effect sizes.

361 The current study is the first to report significant associations between asthma PRS and allergic 362 disease PRS, and COVID-19 severity. A previous study in the UK Biobank found no association between asthma PRS and severe COVID-19 [14]. However, the direction of association was 363 positive, and asthma diagnosis was significantly associated with COVID-19 severity (OR=1.39), 364 365 in line with epidemiological and clinical evidence [7]. In contrast to Zhu, Hasegawa [14], in our subsample with European ancestry, the PRS for asthma was associated with a 1.61-fold increase 366 367 in the odds of classification into the most severe COVID-19 category, as well as with the full 368 range of COVID-19 symptom severity, independently of respiratory diagnoses. Our focus on patients with a wide range of COVID-19 symptoms, in contrast with Zhu, Hasegawa [14] focus 369 370 on hospitalized cases with severe COVID-19, might be a strength of the current study that 371 explains different findings. Other potential explanations include demographic differences between the samples, data collection at different phases of the pandemic, and differences in 372 373 sample sizes.

374

Allergic disease PRS based on the related GWAS of cases with doctor-diagnosed hay fever, allergic rhinitis, eczema, or allergic asthma doubled the odds of classification into the most severe COVID-19 category in participants of European ancestry (OR=1.97), adjusting for demographic covariates and respiratory diagnoses. Taken together, these results are consistent with the evidence for the role of immune function genes implicated in COVID-19 severity [8]. It is possible that asthma and allergic sensitization contribute to the pathobiology of severe COVID-19, such as expression of the SARS-CoV-2 receptor ACE2 [27, 28], and that asthma and

allergic disease PRS capture these effects. Another possibility is that both asthma and atopic
disease have a proclivity toward a TH2 immune response and thus may contribute to a TH1 or
TH2 imbalance and a poorer outcome [29]. Finally, despite the substantial genetic correlation
between asthma and mental health [30], responders' history of PSTD and MDD did not explain
the association between asthma PRS and COVID-19 severity.

387

Contrary to our hypotheses, PRS for coronary artery disease and type II diabetes were not 388 associated with any COVID-19 outcomes. Cardiovascular and other obesity-related disorders 389 have previously been highlighted as risk factors for severe COVID-19 presentation and residual 390 symptoms [7, 31], including in our sample [2]. However, our findings suggest that genetic 391 vulnerability to these conditions might not contribute prominently to COVID-19 severity. A 392 393 study found a significant association between BMI PRS and higher risk of severe COVID-19 outcomes such as hospitalization; however, the effect sizes were small (OR=1.14) [32] and were 394 395 below effect sizes the present study was powered to detect. Furthermore, the previous study did 396 not find significant relationships between COVID-19 outcomes and PRS for BMI-adjusted waist-to-hip ratio and BMI-adjusted waist circumference, indicating an overall weak association 397 between genetic vulnerability to high weight and COVID-19 severity, consistent with the current 398 399 findings for PRS developed for coronary artery disease and type II diabetes.

400

The PRS based on the largest GWAS to date comparing hospitalized COVID-19 cases to healthy controls [9] was significantly associated with a 1.35-fold increase in the odds of having had severe COVID-19. This finding agrees with previous studies based on large cohorts such as the UK Biobank which found that COVID-19 PRS were associated with severe COVID-19

405 outcomes [10-12]. For example, Nakanishi, Pigazzini [10] reported that COVID-19 PRS 406 predicted death or severe respiratory failure (OR=1.70). Similarly, Horowitz, Kosmicki [11] reported that a PRS based on the top six SNPs associated with COVID-19 predicted a 1.38-fold 407 408 increased risk of hospitalization and a 1.58-fold increased risk of severe disease in European ancestry participants, with results replicated in other ancestries. Importantly, COVID-19 severity 409 PRS were not associated with the full spectrum of COVID-19 symptoms in our population and 410 did not associate with residual post-acute COVID-19 syndrome. This finding adds novel 411 evidence that the COVID-19 PRS specifically captures genetic vulnerability to a severe response 412 413 to SARS-CoV-2 infection.

414

415 **Strengths and Limitations**

The strengths of the current study include a large sample with well-characterized COVID-19 416 417 symptomatology, follow-up information on post-acute COVID-19 sequelae, and application of 418 PRS based on the largest discovery samples available for each disease. Nonetheless, we also note 419 several limitations. First, although we demonstrated that genotyped patients did not differ 420 significantly from non-genotyped patients, the specific inclusion and exclusion criteria might result in selection bias, contributing to the broader non-representativeness of the WTC cohort to 421 the general population. The proportion of individuals with ancestry admixture in the WTC 422 cohort is too small to allow genetic analyses in non-Northern European ancestries. Nonetheless, 423 424 for transparency, we opted to report analyses in the total sample as well as the European ancestry subsample, and results are notably similar. In either sample, we were underpowered to detect 425 very small associations. Relatedly, the WTC responder population is primarily male, and the 426 number of females was insufficient to explore sex differences. Moreover, we were underpowered 427

to stratify the sample by age, respiratory illness, or other characteristics related to COVID-19
severity. We have adjusted for these covariates in our analyses, but acknowledge that the
findings arising from the current study may not generalize to other populations.

431 Second, some participants were included based on infection information that was not independently verified by the study team. However, these participants reported testing positive 432 433 for SARS-CoV-2 through one of the available testing methods and did not differ from verified 434 participants on any characteristics except COVID-19 severity, which is due to verified records being available for hospitalized responders, suggesting that misclassification was likely to be 435 436 minimal. The COVID-19 verification status was included as a covariate in all analyses. Third, 437 different viral strains emerged and vaccination status changed over the course of this study. These factors can affect infection susceptibility and COVID-19 disease severity. For example, 438 439 COVID-19 vaccines are very effective in lowering infection and disease severity [33, 34], which 440 in turn could decrease the role of host genetics in COVID-19 outcomes, attenuating observed PRS associations. Moreover, in vaccinated individuals, PRS associations with COVID-19 441 442 severity could instead reflect vulnerability to vaccine breakthroughs. We did not have sufficient 443 data to investigate these issues, which likely have contrasting effects on our results, and limit 444 their comparability to studies conducted at different points in the pandemic. Future studies of PRS are needed to model complex interactions between these factors. 445

Fifth, the current study used asthma PRS based on a GWAS of a broadly defined asthma. However, asthma is a complex and heterogeneous condition, with allergic and non-allergic asthmas demonstrating partially different genetic etiologies [24, 35, 36]. Accordingly, PRS for specific asthma subtypes based on allergy and age-at-onset have been shown to differentially associate with outcomes such as BMI [37]. Thus, future work should replicate and clarify

451 whether observed associations between asthma PRS and COVID-19 severity differ across 452 asthma subtypes.

453 **Conclusions**

The current translational study found that PRS for asthma, allergic disease, and COVID-19 hospitalization were associated with an increased risk for severe COVID-19 presentation among community-based individuals infected with SARS-CoV-2. Asthma PRS was also associated with higher COVID-19 severity across the full range of COVID-19 symptoms. The current effect sizes were small, but with additional research, known genetic vulnerability factors might help to identify individuals at an increased risk for a severe course of COVID-19 disease.

460

461 Acknowledgements

462 We thank participants for their commitment to the project

463 **Funding Source**

The study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin. We would like to acknowledge ongoing funding to monitor World Trade Center responders as part of the WTC Health and Wellness Program (CDC 200-2011-39361). The findings and

469 conclusions in this article are those of the authors and do not represent the official position of470 CDC.

471 Conflict of Interest Statement

- 472 The authors declare no conflict of interest. The funders had no role in the design of the study; in
- the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the
- 474 decision to publish the results.

475 Data Availability Statement

476 Data file is available at synapse.org (https://www.synapse.org/#!Synapse:syn44590167,
477 doi:10.7303/syn44590167)

479 **References**

- 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
 real time. The Lancet infectious diseases. 2020;20(5):533-4.
- 482 2. Lhuillier E, Yang Y, Morozova O, Clouston SA, Yang X, Waszczuk MA, et al. The
- 483 Impact of World Trade Center Related Medical Conditions on the Severity of COVID-19
- 484 Disease and Its Long-Term Sequelae. International Journal of Environmental Research and
 485 Public Health. 2022;19(12):6963.
- 3. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Postacute COVID-19 syndrome. Nature medicine. 2021;27(4):601-15.
- 488 4. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and
 489 long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA
 490 network open. 2021;4(10):e2128568-e.
- 491 5. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
 492 associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.
- 493 6. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-existing traits
 494 associated with Covid-19 illness severity. PLoS One. 2020;15(7):e0236240.
- 495 7. Gao Yd, Ding M, Dong X, Zhang Jj, Kursat Azkur A, Azkur D, et al. Risk factors for
 496 severe and critically ill COVID 19 patients: a review. Allergy. 2021;76(2):428-55.
- 8. Niemi ME, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. Nature
 Reviews Genetics. 2022:1-14.
- 499 9. COVID-19 Host Genetics Initiative. The COVID-19 host genetics initiative, a global
 500 initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS501 CoV-2 virus pandemic. European Journal of Human Genetics. 2020;28(6):715.

502 10. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et

- al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity
- and mortality. The Journal of clinical investigation. 2021;131(23).

505 11. Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al.

506 Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and

507 yields risk scores associated with severe disease. Nature genetics. 2022;54(4):382-92.

Huang Q-M, Zhang P-D, Li Z-H, Zhou J-M, Liu D, Zhang X-R, et al. Genetic risk and
chronic obstructive pulmonary disease independently predict the risk of incident severe COVID-

510 19. Annals of the American Thoracic Society. 2022;19(1):58-65.

511 13. Crossfield SS, Chaddock NJ, Iles MM, Pujades-Rodriguez M, Morgan AW. Interplay
512 between demographic, clinical and polygenic risk factors for severe COVID-19. International
513 Journal of Epidemiology. 2022.

I4. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and
its genetic predisposition with the risk of severe COVID-19. Journal of Allergy and Clinical
Immunology. 2020;146(2):327-9. e4.

15. Morozova O, Clouston SA, Valentine J, Newman A, Carr M, Luft BJ. COVID-19
cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January–August
2020: A cohort of World Trade Center responders. PLoS One. 2021;16(7):e0254713.

16. Waszczuk MA, Docherty AR, Shabalin AA, Miao J, Yang X, Kuan P-F, et al. Polygenic
prediction of PTSD trajectories in 9/11 responders. Psychological Medicine. 2020:1-9.

Huckins LM, Johnson JS, Cancelmo L, Diab O, Schaffer J, Cahn L, et al. Polygenic
regulation of PTSD severity and outcomes among World Trade Center responders. medRxiv.
2021:2020.12. 06.20244772.

- 18. Dasaro CR, Holden WL, Berman KD, Crane MA, Kaplan JR, Lucchini RG, et al. Cohort
 Profile: World Trade Center Health Program General Responder Cohort. International Journal of
 Epidemiology. 2015.
- 528 19. Cohen J. The cost of dichotomization. Applied psychological measurement.
 529 1983;7(3):249-53.
- 530 20. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization
 531 of quantitative variables. Psychological methods. 2002;7(1):19.
- 532 21. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
 533 reference panel of 64,976 haplotypes for genotype imputation. Nature genetics.
 534 2016;48(10):1279.
- 535 22. Euesden J, Lewis CM, O'Reilly PF. PRSice: polygenic risk score software.
 536 Bioinformatics. 2015;31(9):1466-8.
- Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research
 review: polygenic methods and their application to psychiatric traits. Journal of Child
 Psychology and Psychiatry. 2014;55(10):1068-87.
- Zhu Z, Lee PH, Chaffin MD, Chung W, Loh P-R, Lu Q, et al. A genome-wide cross-trait
 analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic
 diseases. Nature genetics. 2018;50(6):857-64.
- 543 25. Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded
 544 view on the genetic architecture of coronary artery disease. Circulation research.
 545 2018;122(3):433-43.

- Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association
 analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.
 Nature communications. 2018;9(1):1-14.
- 549 27. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al.
- Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.
- Journal of Allergy and Clinical Immunology. 2020;146(1):203-6. e3.
- 552 28. Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, et al. Type 2 553 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway 554 epithelium. Nature communications. 2020;11(1):1-18.
- 555 29. Gil-Etayo FJ, Suàrez-Fernández P, Cabrera-Marante O, Arroyo D, Garcinuño S, Naranjo
 556 L, et al. T-helper cell subset response is a determining factor in COVID-19 progression.
 557 Frontiers in cellular and infection microbiology. 2021;11:624483.
- 558 30. Zhu Z, Zhu X, Liu C-L, Shi H, Shen S, Yang Y, et al. Shared genetics of asthma and 559 mental health disorders: a large-scale genome-wide cross-trait analysis. Eur Respir J. 2019;54(6).
- 560 31. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al.
 561 Association of obesity with disease severity among patients with coronavirus disease 2019.
 562 Obesity. 2020;28(7):1200-4.
- 32. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and
 its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort
 data. Metabolism. 2020;112:154345.
- 33. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
 COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60.

568	34.	Mohammed I, N	Jauman A,	Paul P,	Ganesan S,	Chen K-H	I, Jalil SMS	et al.	The efficacy	•
-----	-----	---------------	-----------	---------	------------	----------	--------------	--------	--------------	---

- and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and
- 570 mortality: A systematic review. Hum Vaccin Immunother. 2022;18(1):2027160.
- 571 35. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective.
- 572 Immunological reviews. 2011;242(1):10-30.
- 573 36. Zhu Z, Hasegawa K, Camargo Jr CA, Liang L. Investigating asthma heterogeneity
- through shared and distinct genetics: Insights from genome-wide cross-trait analysis. Journal of
- 575 Allergy and Clinical Immunology. 2021;147(3):796-807.
- 576 37. Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, et al. Shared genetic and
- 577 experimental links between obesity-related traits and asthma subtypes in UK Biobank. Journal of

Allergy and Clinical Immunology. 2020;145(2):537-49.

579

580

581 Supporting Information

- 582 Table S1. Associations among PRS used in the study
- 583 **Table S2. Descriptive statistics for participants of all ancestries**
- Table S3. Associations between allergic disease and asthma PRS and COVID-19 severity
- and residual symptoms in participants of all ancestries
- 586 Table S4. Associations between coronary artery disease and type II diabetes PRS and
- 587 COVID-19 severity and residual symptoms in participants of all ancestries

- 588 Table S5. Associations between COVID-19 PRS and COVID-19 severity and residual
- 589 symptoms in participants of all ancestries
- 590 Table S6. Mental health and associations between COVID-19 outcomes and PRS for
- 591 asthma in European ancestry participants